<DOC>
	<DOC>NCT00871182</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Signed written informed consent 40 75 years of age Females of nonchild bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods COPD diagnosis Current/former smokers with at least a 10 packyear history of cigarette smoking Patients with established clinical history of COPD and severity defined as a postipratropium FEV1/FVC ratio of ≤0.70 and FEV1 ≥50 and ≤85% of predicted normal at Screening Must demonstrate reversibility to ipratropium demonstrated by a &gt;200 mL improvement over baseline and/or &gt;12% and &gt;150 mL improvement over baseline Patients willing to stay at study site for at least 24 hours on each test day Women who are pregnant or lactating Primary diagnosis of asthma Alpha1 antitrypsin deficiency as the cause of COPD Active pulmonary diseases Prior lung volume reduction surgery Abnormal chest Xray (or CT scan) not due to the presence of COPD Hospitalized due to poorly controlled COPD within 24 weeks of Screening Unable to perform acceptable spirometry Poorly controlled COPD in prior 6weeks, defined as the occurrence of acute worsening of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring treatment prescribed by a physician Clinically significant medical conditions Symptomatic prostatic hypertrophy or bladder neck obstruction Known narrowangle glaucoma Lower respiratory tract infection requiring antibiotics in past 6 weeks Clinically significant abnormal ECG Clinically significant uncontrolled hypertension Positive Hepatitis B surface antigen or Hepatitis C antibody Cancer that has not been in complete remission for at least 5 years History of hypersensitivity to any beta2agonists or anticholinergics History of severe milk protein allergy Known or suspected history of alcohol or drug abuse Medically unable to withhold short acting bronchodilators for 6hours Use of the medications below in specified time interval prior to Screening: 3 months: depot corticosteroids, intraarticular corticosteroids; 6 weeks: oral corticosteroids, antibiotics administered for a COPD exacerbation; and 1 month: Pglycoprotein inhibitors, CYP450 3A4 inhibitors, ICS &gt;1000 μg/day of fluticasone propionate or equivalent The following COPD medications need to be stopped and switched to appropriate replacement therapies: tiotropium, oral beta2 agonists, LABAs, combination corticosteroid/LABAs, theophylline, leukotriene inhibitors,cromoglycate and nedocromil Use of the following medications is prohibited: tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, betaadrenergic antagonists, anticonvulsants (barbiturates, hydantoins, and carbamazepine and phenothiazines Receiving longtermoxygen or nocturnal oxygen therapy for &gt;12 hours a day Diagnosis of sleep apnea that is uncontrolled Participation in acute phase of pulmonary rehabilitation in prior 4 weeks Will enter acute phase of pulmonary rehabilitation program during study Unable to comply with study procedures Affiliated with Investigator site Questionable validity of consent Use of investigational study drug/participation in clinical study in the last 30 days or 5 half lives prior to Screening, whichever is longer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>obstructive lung diseases</keyword>
	<keyword>Tiotropium</keyword>
</DOC>